1
|
Protiere C, Fressard L, Mora M, Meyer L, Préau M, Suzan-Monti M, Lelièvre JD, Lambotte O, Spire B. Characterization of Physicians That Might Be Reluctant to Propose HIV Cure-Related Clinical Trials with Treatment Interruption to Their Patients? The ANRS-APSEC Study. Vaccines (Basel) 2020; 8:vaccines8020334. [PMID: 32585921 PMCID: PMC7350235 DOI: 10.3390/vaccines8020334] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 06/04/2020] [Accepted: 06/17/2020] [Indexed: 12/25/2022] Open
Abstract
HIV cure-related clinical trials (HCRCT) with analytical antiretroviral treatment interruptions (ATIs) have become unavoidable. However, the limited benefits for participants and the risk of HIV transmission during ATI might negatively impact physicians’ motivations to propose HCRCT to patients. Between October 2016 and March 2017, 164 French HIV physicians were asked about their level of agreement with four viewpoints regarding HCRCT. A reluctance score was derived from their answers and factors associated with reluctance identified. Results showed the highest reluctance to propose HCRCT was among physicians with a less research-orientated professional activity, those not informing themselves about cure trials through scientific literature, and those who participated in trials because their department head asked them. Physicians’ perceptions of the impact of HIV on their patients’ lives were also associated with their motivation to propose HCRCT: those who considered that living with HIV means living with a secret were more motivated, while those worrying about the negative impact on person living with HIV’s professional lives were more reluctant. Our study highlighted the need to design a HCRCT that minimizes constraints for participants and for continuous training programs to help physicians keep up-to-date with recent advances in HIV cure research.
Collapse
Affiliation(s)
- Christel Protiere
- Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, 13005 Marseille, France; (L.F.); (M.M.); (M.S.-M.); (B.S.)
- Correspondence:
| | - Lisa Fressard
- Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, 13005 Marseille, France; (L.F.); (M.M.); (M.S.-M.); (B.S.)
| | - Marion Mora
- Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, 13005 Marseille, France; (L.F.); (M.M.); (M.S.-M.); (B.S.)
| | - Laurence Meyer
- INSERM, U1018, Université Paris-Sud 11, AP-HP, Hôpital de Bicêtre, Département D’épidémiologie, 94270 Le Kremlin-Bicêtre, France;
| | - Marie Préau
- GRePS, Lyon 2 Université, 69676 Bron, France;
| | - Marie Suzan-Monti
- Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, 13005 Marseille, France; (L.F.); (M.M.); (M.S.-M.); (B.S.)
| | - Jean-Daniel Lelièvre
- INSERM, U955, Equipe 16, Université Paris Est, Faculté de médecine, Vaccine Research Institute, 94000 Créteil, France;
| | - Olivier Lambotte
- Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service de Médecine Interne et Immunologie Clinique, INSERM, U1184, 94270 Le Kremlin-Bicêtre, France;
- Immunology of Viral Infections and Autoimmune Diseases, Université Paris Sud, UMR 1184, 94270 Le Kremlin-Bicêtre, France
- CEA, DSV/iMETI, IDMIT, 92260 Fontenay-aux-Roses, France
| | - Bruno Spire
- Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, 13005 Marseille, France; (L.F.); (M.M.); (M.S.-M.); (B.S.)
| | | |
Collapse
|